deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
April 25 2024 - 3:00AM
deepull unveils 1 hour, direct-from-blood
multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID
2024
UllCORE is designed to transform life-saving clinical decision
making for sepsis patients
Barcelona, Spain – 25 April 2024
– deepull, a medical diagnostics company developing
culture-free diagnostic solutions for rapid pathogen identification
for sepsis and other acute infections, today announces the
unveiling of its UllCORE diagnostic system, currently in
development, with its first application in early sepsis
detection.
UllCORE is a benchtop diagnostic system designed
to deliver 50 reportable results in one hour covering 95% of
sepsis-causing pathogens and resistance genes. The real-time
multiplex PCR system extracts total microbial DNA from 8 mL of
whole blood, circumventing the lengthy blood culture process. The
assay includes a wide range of bacterial targets, fungi, and
genetic determinants of antibiotic resistance. UllCORE’s speed and
sensitivity will enable clinicians to make better decisions and
reduce the risk of over- or under-treatment with antibiotics, in
turn supporting the fight against antimicrobial resistance within
hospitals. Beyond sepsis, deepull believes its system has the
potential to be applicable to a wide range of acute infections.
Today’s unveiling is the result of years of
research, enabled by funding from a range of international
investors. The product will be debuted at this year’s ESCMID Global
2024 conference, taking place in Barcelona from 27-30 April. Over
the coming months deepull is seeking to develop strong partnerships
with hospitals and laboratories in anticipation of initiating
clinical trials next year. These next steps will be driven forward
by the expert deepull team, recently bolstered with the
appointments of Dr Kimberle Chapin as Chief Medical Officer and
Wade Stevenson as Chief Marketing and Sales Officer.
The challenge to identify and treat sepsis is
well documented. Sepsis is a contributing factor to 1 in 3 hospital
deaths in the US, and septic shock is associated with a mortality
rate of 30-40% globally. Early diagnosis is a challenge as the
symptoms are non-specific and easy to miss. Current sepsis testing
is dominated by complex blood culture tests which can take days to
deliver results. This method is now over 40 years old and is
limited to ‘viable’ organisms, missing a wide range of additional
microbial analytes that can be found in blood.
Jordi Carrera, Chief Executive Officer
and Co-Founder of deepull, commented: “Introducing the
UllCORE platform and its unique capabilities to the market is a
significant milestone for deepull. We are encouraged by early
results based on prospectively obtained specimens from septic
patients and look forward to initiating clinical trials next year,
as well as refining the platform ahead of commercial launch. We
believe our UllCORE system could transform the standard of care for
sepsis diagnosis, for the benefit of patients globally.”
Dr Kimberle Chapin, newly appointed
Chief Medical Officer, added: “My experience in the
diagnosis of infectious diseases has made it clear to me that more
needs to be done to support clinical decision making in the
hospital setting. UllCORE has been designed with hospital
laboratories in mind, and I look forward to sharing more about its
capabilities at ESCMID.”
To connect with the deepull team at ESCMID,
please email contact@deepull.com.
-Ends-
Notes to editors
About deepull
deepull is a medical diagnostics company
developing culture-free diagnostic solutions for sepsis and acute
infections. Founded in 2020 in Barcelona by the founders of STAT-Dx
(sold to QIAGEN in 2018), deepull has assembled a team of
world-class experts to create rapid and accessible diagnostic
solutions. Visit www.deepull.com for more and follow us on
LinkedIn.
deepull is developing a 1 hour,
direct-from-blood PCR test targeting 95% of sepsis-causing
pathogens. The test will extract total microbial DNA from 8 mL of
whole blood and include 50 reportable results. The test runs on the
deepull UllCORE instrument; a benchtop system with sample-to-result
automation being designed to meet the needs of any hospital
clinical laboratory.
For more information, please contact:
deepull
Agustina
Boullaude Email:
aboullaude@deepull.com
ICR Consilium
Amber Fennell / Lucy Featherstone
Email: deepull@consilium-comms.com